Natalizumab Treatment of Progressive Multiple Sclerosis
Condition(s):Primary Progressive Multiple Sclerosis; Secondary Progressive Multiple SclerosisLast Updated:February 17, 2012Completed
Hide Studies Not Open or Pending
Condition(s):Primary Progressive Multiple Sclerosis; Secondary Progressive Multiple SclerosisLast Updated:February 17, 2012Completed
Condition(s):Relapsing Multiple SclerosisLast Updated:March 4, 2024Recruiting
Condition(s):Multiple Sclerosis; miRNA; Epigenetic; BiomarkerLast Updated:February 26, 2021Completed
Condition(s):Systemic SclerosisLast Updated:July 11, 2019Unknown status
Condition(s):Multiple SclerosisLast Updated:August 3, 2018Completed
Condition(s):Multiple SclerosisLast Updated:March 1, 2019Completed
Condition(s):Multiple Sclerosis; Neuromyelitis Optica Spectrum DisordersLast Updated:August 9, 2016Unknown status
Condition(s):Sclerosis, MultipleLast Updated:November 2, 2023Terminated
Condition(s):Amyotrophic Lateral SclerosisLast Updated:August 19, 2020Unknown status
Condition(s):Multiple Sclerosis; Peripheral NeuropathyLast Updated:March 3, 2017Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.